The FDA approved a new indication for the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy), both made by Bristol-Myers Squibb: first-line treatment of adults with malignant pleural mesothelioma (MPM) that cannot be removed by surgery.
This is the first drug regimen approved for mesothelioma in 16 years and the second approved systemic therapy for mesothelioma, the agency said.
“The combination of nivolumab and ipilimumab could become a new front-line standard of care